shutterstock_504234469_garrykillian
GarryKillian / Shutterstock.com
22 March 2021Big PharmaSarah Kostiuk-Smith

Got a patent, now where to validate?

Securing a European patent covering your drug candidate, or a potentially valuable formulation or dosage regimen, is certainly cause for celebration. However, it necessitates a big decision: where do you validate your new patent? That is, which of the 38 European Patent Convention (EPC) countries spanning from Iceland to Turkey will you select for the patent to be effective and enforceable?

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
1 July 2026   Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country.
Big Pharma
18 June 2026   Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study.
Big Pharma
15 April 2026   The Danish pharma giant is turning to artificial intelligence as it faces patent expiry, falling shares and intensifying competition from Eli Lilly.